April 03, 2026
For over half a century, the management of autoimmune thyroid disease has mandated difficult clinical compromises. In Graves' disease (GD), despite a contemporary shift toward thyroid preservation using antithyroid drugs, these medications often fail to induce durable remission and do not rectify the underlying autoimmune process. Concurrently, the treatment of active thyroid eye disease (TED) has historically relied on systemic corticosteroids, which offer limited relief for structural issues such as proptosis and carry significant systemic toxicities. Endocrinology is currently experiencing a major recalibration toward highly targeted, pathophysiology-guided immunotherapies designed to spare organs and directly address the root causes of autoimmune thyroid disease.
"For decades, we accepted irreversible thyroid destruction or the extensive side effect profile of high-dose glucocorticoids as necessary trade-offs with effective drug therapy for these conditions," says David Toro Tobon, M.D., an endocrinologist at Mayo Clinic in Rochester, Minnesota. "Today, our granular understanding of the thyrotropin receptor autoantibody (TRAb) lifecycle allows us to target the fundamental autoimmune process directly, moving us closer to the ultimate goal of sustained, drug-free remission. Importantly, it is crucial to recognize that this is still mainly a 'work in progress' area. Except for certain approved targeted therapies for TED, the vast majority of these novel agents remain investigational and are currently undergoing rigorous clinical trial evaluation."
The paradigm shift relies on a pathophysiology-centric framework, which was discussed in recently published articles in both the Journal of Clinical Endocrinology & Metabolism and the European Journal of Endocrinology. In GD, novel agents aim to interrupt TRAb production, enhance its systemic clearance or neutralize its target at the receptor level. Similarly, the management of TED has been revolutionized by targeting the precise molecular cross-talk between the TSH receptor and the insulin-like growth factor-1 receptor (IGF-1R) within the orbital microenvironment. While first-generation targeted therapies such as intravenous teprotumumab proved highly efficacious for TED, the logistical burden of high cost, frequent infusions and nonnegligible safety profiles highlight the need for next-generation agents.
Leading the charge: Active clinical trials at Mayo Clinic
To bridge these therapeutic gaps, Marius N. Stan, M.D., an endocrinologist and a principal investigator at Mayo Clinic in Rochester, Minnesota, is spearheading efforts to evaluate the most advanced therapies currently in the pipeline. Under his guidance, Endocrinology in Rochester, Minnesota, is actively participating in several pivotal clinical trials.
One major focus is targeting TRAb clearance in GD through the global FORWARD study, where his team is assessing IMVT-1402 in adults who remain hyperthyroid despite standard antithyroid drug therapy. As a second-generation, subcutaneously administered neonatal Fc receptor (FcRn) inhibitor, this agent is designed to profoundly deplete pathogenic IgG without inducing the lipid elevations seen with earlier medications.
Simultaneously, for patients with active or chronic TED, the division is enrolling participants in the phase 3 REVEAL studies. These trials are rigorously evaluating VRDN-003, an IGF-1R antagonist engineered to have a significantly prolonged half-life of 40 to 50 days. VRDN-003 is administered via low-frequency subcutaneous injections every four or eight weeks. It's designed to maintain robust clinical responses while drastically reducing the patient's treatment burden.
Another promising step toward precision medicine in this field comes from participation in the phase 1 NEXUS study. This first-in-human trial evaluates MER511, a completely novel, bifunctional agent engineered with a TSHR-mimetic domain to capture circulating TRAb and a clearance domain to eliminate it via the liver, leaving the rest of the humoral immune system entirely intact.
Conclusion
These active research efforts reflect a significant and important shift in management of patients with autoimmune thyroid disease. By offering patients access to these cutting-edge therapeutic modalities, the goal of achieving durable remission, preserving the native thyroid gland and preventing the disfiguring ravages of TED is becoming a clinical reality.
For more information
Stan MN, et al. Graves' disease: A new era of pathophysiology-guided therapeutics. Journal of Clinical Endocrinology & Metabolism. 2026;111:1-13.
Toro-Tobon D, et al. The evolving landscape of thyroid eye disease: Present and future. European Journal of Endocrinology. 2025;193:R15.
Refer a patient to Mayo Clinic.